Vinva Investment Management Ltd Has $5.63 Million Position in Pfizer Inc. (NYSE:PFE)

Vinva Investment Management Ltd increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 312.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,465 shares of the biopharmaceutical company’s stock after purchasing an additional 146,564 shares during the quarter. Vinva Investment Management Ltd’s holdings in Pfizer were worth $5,628,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company’s stock valued at $1,101,713,000 after purchasing an additional 6,977,587 shares in the last quarter. Public Sector Pension Investment Board boosted its stake in shares of Pfizer by 107.9% in the 3rd quarter. Public Sector Pension Investment Board now owns 1,705,865 shares of the biopharmaceutical company’s stock valued at $49,368,000 after purchasing an additional 885,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Pfizer by 4.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,427,095 shares of the biopharmaceutical company’s stock worth $70,240,000 after acquiring an additional 98,873 shares in the last quarter. Providence Capital Advisors LLC boosted its position in shares of Pfizer by 0.7% during the 3rd quarter. Providence Capital Advisors LLC now owns 113,949 shares of the biopharmaceutical company’s stock valued at $3,298,000 after purchasing an additional 806 shares in the last quarter. Finally, CreativeOne Wealth LLC grew its stake in Pfizer by 62.3% during the third quarter. CreativeOne Wealth LLC now owns 117,673 shares of the biopharmaceutical company’s stock worth $3,405,000 after purchasing an additional 45,163 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Sanford C. Bernstein began coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Wednesday, October 23rd. Barclays upped their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Pfizer Trading Up 0.2 %

Shares of PFE opened at $25.83 on Thursday. The firm has a market cap of $146.38 billion, a P/E ratio of 34.91, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business has a 50-day moving average of $27.97 and a 200 day moving average of $28.52.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The company had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period last year, the firm earned ($0.17) EPS. Pfizer’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be issued a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.50%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares of the company’s stock, valued at approximately $282,400. This represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.